[go: up one dir, main page]

PE20090728A1 - PEPTIDO scFV, ACIDOS NUCLEICOS QUE LO CODIFICAN Y COMPOSICIONES QUE LO CONTIENEN - Google Patents

PEPTIDO scFV, ACIDOS NUCLEICOS QUE LO CODIFICAN Y COMPOSICIONES QUE LO CONTIENEN

Info

Publication number
PE20090728A1
PE20090728A1 PE2008000709A PE2008000709A PE20090728A1 PE 20090728 A1 PE20090728 A1 PE 20090728A1 PE 2008000709 A PE2008000709 A PE 2008000709A PE 2008000709 A PE2008000709 A PE 2008000709A PE 20090728 A1 PE20090728 A1 PE 20090728A1
Authority
PE
Peru
Prior art keywords
peptide
domain
amino acid
scfv
compositions
Prior art date
Application number
PE2008000709A
Other languages
English (en)
Inventor
James Burnie
Philipp Wechner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090728A1 publication Critical patent/PE20090728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN PEPTIDO scFV QUE COMPRENDE UN DOMINIO VH Y UN DOMINIO VL ENLAZADOS POR UN ESPACIADOR DE AMINOACIDOS, DONDE EL DOMINIO VH ES 80% IDENTICA A LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO:64, EL DOMINIO VL ES 80% IDENTICA A LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO:66 Y EL PEPTIDO scFV COMPRENDE LA SUSTITUCION O LA SUPRESION DE UN AMINOACIDO EN EL DOMINIO VH EN LA POSICION CORRESPONDIENTE A C28. TAMBIEN ESTA REFERIDA A UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA AL PEPTIDO scFV, UNA COMPOSICION FARMACEUTICA, UN VECTOR, UNA CELULA HUESPED, UN METODO DE PRODUCCION Y UNA COMBINACION QUE CONTIENE EL PEPTIDO scFV Y UN AGENTE ANTIFUNGICO O UN AGENTE CONTRA EL CANCER. DICHO PEPTIDO SE ENLAZA CON LA PROTEINA DE TENSION FUNGICA hsp90 Y ES UTIL EN EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOINMUNES E INFECCIONES FUNGICAS
PE2008000709A 2007-04-27 2008-04-25 PEPTIDO scFV, ACIDOS NUCLEICOS QUE LO CODIFICAN Y COMPOSICIONES QUE LO CONTIENEN PE20090728A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107140 2007-04-27
EP07113353 2007-07-27

Publications (1)

Publication Number Publication Date
PE20090728A1 true PE20090728A1 (es) 2009-07-02

Family

ID=39717534

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000709A PE20090728A1 (es) 2007-04-27 2008-04-25 PEPTIDO scFV, ACIDOS NUCLEICOS QUE LO CODIFICAN Y COMPOSICIONES QUE LO CONTIENEN

Country Status (21)

Country Link
US (3) US20100113355A1 (es)
EP (2) EP2144932A1 (es)
JP (1) JP2010524485A (es)
KR (1) KR20100017387A (es)
CN (1) CN101679517A (es)
AR (1) AR066311A1 (es)
AU (1) AU2008244308A1 (es)
BR (1) BRPI0810827A2 (es)
CA (1) CA2685136A1 (es)
CL (1) CL2008001202A1 (es)
CR (1) CR11059A (es)
EA (1) EA200901441A1 (es)
EC (1) ECSP099765A (es)
GT (1) GT200900276A (es)
IL (1) IL201445A0 (es)
MA (1) MA31384B1 (es)
MX (1) MX2009011595A (es)
PE (1) PE20090728A1 (es)
TN (1) TN2009000442A1 (es)
TW (1) TW200902714A (es)
WO (2) WO2008132152A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
US10487151B2 (en) * 2014-07-23 2019-11-26 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732852A (en) 1981-11-20 1988-03-22 Cetus Corporation Site directed peptidase cleavage
US4670382A (en) 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US4806465A (en) 1984-01-16 1989-02-21 Temple University Of The Commonwealth System Of Higher Education Cytoplasmic antigens of candida albicans and methods of using the same
GB8506373D0 (en) 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
US6583268B2 (en) 2000-01-25 2003-06-24 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
WO2002006990A1 (en) 2000-07-14 2002-01-24 Healthcite, Inc. Method and system for providing medical information
US20060079493A1 (en) * 2001-03-01 2006-04-13 Lawrence Fritz Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition

Also Published As

Publication number Publication date
WO2008132134A1 (en) 2008-11-06
MA31384B1 (fr) 2010-05-03
ECSP099765A (es) 2009-12-28
TN2009000442A1 (en) 2011-03-31
WO2008132134A9 (en) 2009-07-09
GT200900276A (es) 2010-05-21
EA200901441A1 (ru) 2010-04-30
US7722869B2 (en) 2010-05-25
US20090136484A1 (en) 2009-05-28
EP2144932A1 (en) 2010-01-20
KR20100017387A (ko) 2010-02-16
MX2009011595A (es) 2009-12-08
CN101679517A (zh) 2010-03-24
AR066311A1 (es) 2009-08-12
AU2008244308A1 (en) 2008-11-06
BRPI0810827A2 (pt) 2014-10-29
US20100166758A1 (en) 2010-07-01
CR11059A (es) 2009-11-20
CL2008001202A1 (es) 2008-12-19
WO2008132152A1 (en) 2008-11-06
US20100113355A1 (en) 2010-05-06
CA2685136A1 (en) 2008-11-06
EP2152746A1 (en) 2010-02-17
IL201445A0 (en) 2010-06-16
TW200902714A (en) 2009-01-16
JP2010524485A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
PE20090728A1 (es) PEPTIDO scFV, ACIDOS NUCLEICOS QUE LO CODIFICAN Y COMPOSICIONES QUE LO CONTIENEN
PE20121184A1 (es) Moleculas de union a dll-4
PE20070684A1 (es) MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
PE20120001A1 (es) Dominios variables simples anti-albumina de suero mejorados
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
CL2011000672A1 (es) Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.
PE20241128A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
MX347295B (es) Inmunoglobulinas portadoras y usos de las mismas.
MX2007002737A (es) Proteina transportadora para la introduccion de compuestos quimicos en celulas neuronales.
BRPI0610197B8 (pt) anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
PE20201067A1 (es) Anticuerpos anti-csf 1r
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
PE20130738A1 (es) Dominios variables simples de inmunoglobulina anti-vegf
PE20141859A1 (es) Polipeptidos de union a cx3cr1
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
NZ598039A (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CL2009001284A1 (es) Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos
ATE435870T1 (de) Aus ll-37 abgeleiteten peptidinhibitoren von toxinen
Xing et al. Facile expression and purification of the antimicrobial peptide histatin 1 with a cleavable self-aggregating tag (cSAT) in Escherichia coli
NZ596043A (en) Allergy inhibitor compositions and kits and methods of using the same
CL2008003240A1 (es) Anticuerpo aislado que se unen especificamente a nogoa humano o nig humano; polinucleotido codificante, vector y celula que lo comprende; composicion farmaceutica que lo comprende; metodo de produccion de dicho anticuerpo.
AR028713A1 (es) Inmunizacion de ganado productor de leche con proteinas gapc quiméricas contra infecciones por streptococcus

Legal Events

Date Code Title Description
FD Application declared void or lapsed